Single-cell proteomic identification of novel markers of senescence

项目概要 细胞衰老是与促炎症反应相关的细胞周期停滞的一种稳定形式。就其一而言 另一方面，衰老细胞是肿瘤发生的屏障，促进伤口愈合和胚胎发生。另一方面 另一方面，衰老细胞在衰老和患病的组织中积聚，损害组织更新并有助于 炎症和疾病进展。人体组织中衰老细胞的鉴定和表征将 有助于我们了解人类疾病。因此，在 3 维水平上绘制衰老细胞图 人体组织中的单细胞分辨率是一个重要的生物医学目标。 衰老细胞的准确定位需要可靠的标记来特异性识别衰老细胞。 目前，衰老领域用于明确区分衰老细胞和衰老细胞的标记物有限。 细胞处于其他病理状态。此外，现有的标记并没有解决衰老的异质性。 组织中的细胞。为了克服这些限制，我们建议采用一种新型的单细胞蛋白质组技术 在单细胞水平上研究衰老细胞的蛋白质组，目的是揭示衰老细胞的新标记物 衰老可用于识别和绘制人体组织中衰老细胞的图谱。 我们的小组最近开发了一种新技术，称为单细胞蛋白质组学质量 光谱测定 (SCoPE2)。该平台结合了自动细胞裂解、改进的检测灵敏度和 优化的数据采集和分析，允许检测和定量一个范围内的数千种蛋白质 单细胞。我们应用这项技术来研究胚胎干细胞分化和巨噬细胞 极化，揭示它们的异质性和单细胞水平上蛋白质组的改变。 在此应用中，我们将使用肺部作为模型系统，该系统积累衰老细胞 导致衰老和肺部疾病。在UG3阶段，我们将从自然人的肺部分离衰老细胞 年老的老鼠。分离的衰老细胞与对照细胞一起进行 SCoPE2 程序以 在单细胞水平上量化它们的蛋白质组，使我们能够为潜在的多样性创建独特的特征 衰老细胞群。这将有助于发现衰老细胞的新标记，而这是不可能的 传统技术。在UH3阶段，我们将把这项技术应用到人的肺部，以验证并 识别新的衰老标志物。总的来说，我们将建立识别衰老细胞的新方法 这应该提供新的工具来探测人体组织中的衰老细胞，促进衰老的组织图谱 SenNet 倡议的细胞。此外，这项研究有可能揭示衰老的新生物学， 解决单细胞水平的异质性和蛋白质组改变。

PROJECT SUMMARY Cellular senescence is a stable form of cell cycle arrest associated with pro-inflammatory responses. On the one hand, senescent cells are a barrier for tumorigenesis and promote wound healing and embryogenesis. On the other hand, senescent cells accumulate in aged and diseased tissues, where they impair tissue renewal and contribute to inflammation and disease progression. Identification and characterization of senescent cells in human tissues will contribute to our understanding of human diseases. Thus, mapping senescent cells at the 3-dimensional level and single-cell resolution in human tissues is an important biomedical objective. Accurate mapping of senescent cells requires reliable markers to specifically identify senescent cells. Currently the senescence field has limited markers to unambiguously distinguish between senescent cells and cells in other pathological states. In addition, the available markers do not address the heterogeneity of senescent cells in tissues. To overcome these limitations, we propose to employ a novel single-cell proteomic technology to investigate the proteomes of senescent cells at the single-cell level, with the goal to reveal novel markers of senescence which can be used to identify and map senescent cells in human tissues. Our group has recently developed a novel technology termed Single-Cell ProtEomics by Mass Spectrometry (SCoPE2). This platform combines automated cell lysis, improved detection sensitivity, and optimized data acquisition and analyses, allowing detection and quantification of thousands of proteins within a single cell. We have applied this technology to study embryonic stem cell differentiation and macrophage polarization, revealing their heterogeneity and alterations of proteomes at the single-cell level. In this application, we will use the lung as a model system, which accumulate senescent cells that contribute to aging and lung diseases. In the UG3 phase, we will isolate senescent cells from the lungs of naturally aged mice. The isolated senescent cells together with control cells will be subjected to SCoPE2 procedure to quantify their proteomes at the single-cell level, allowing us to create unique signatures for potentially diverse senescent cell populations. This will help discover novel markers of senescent cells that are not possible with traditional technologies. In the UH3 phase, we will apply this technology to human lungs, to validate and to identify new markers of senescence. In aggregate, we will establish new ways of identifying senescent cells that should offer new tools to probe senescent cells in human tissues, facilitating tissue mapping of senescent cells of the SenNet initiative. In addition, this study has the potential to reveal new biology of senescence, addressing the heterogeneity and proteome alterations at the single-cell level.